194 related articles for article (PubMed ID: 32104479)
1. Exploring the relationship of hyaluronic acid molecular weight and active targeting efficiency for designing hyaluronic acid-modified nanoparticles.
Zhong L; Liu Y; Xu L; Li Q; Zhao D; Li Z; Zhang H; Zhang H; Kan Q; Sun J; He Z
Asian J Pharm Sci; 2019 Sep; 14(5):521-530. PubMed ID: 32104479
[TBL] [Abstract][Full Text] [Related]
2. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
3. Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy.
Zhong L; Xu L; Liu Y; Li Q; Zhao D; Li Z; Zhang H; Zhang H; Kan Q; Wang Y; Sun J; He Z
Acta Pharm Sin B; 2019 Mar; 9(2):397-409. PubMed ID: 30972285
[TBL] [Abstract][Full Text] [Related]
4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
5. CD44-Targeted Carriers: The Role of Molecular Weight of Hyaluronic Acid in the Uptake of Hyaluronic Acid-Based Nanoparticles.
Chiesa E; Greco A; Riva F; Dorati R; Conti B; Modena T; Genta I
Pharmaceuticals (Basel); 2022 Jan; 15(1):. PubMed ID: 35056160
[TBL] [Abstract][Full Text] [Related]
6. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid-modified manganese dioxide-enveloped hollow copper sulfide nanoparticles as a multifunctional system for the co-delivery of chemotherapeutic drugs and photosensitizers for efficient synergistic antitumor treatments.
Li X; Pan Y; Zhou J; Yi G; He C; Zhao Z; Zhang Y
J Colloid Interface Sci; 2022 Jan; 605():296-310. PubMed ID: 34329981
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response.
Mizrahy S; Raz SR; Hasgaard M; Liu H; Soffer-Tsur N; Cohen K; Dvash R; Landsman-Milo D; Bremer MG; Moghimi SM; Peer D
J Control Release; 2011 Dec; 156(2):231-8. PubMed ID: 21745506
[TBL] [Abstract][Full Text] [Related]
10. One-pot preparation of hyaluronic acid-coated iron oxide nanoparticles for magnetic hyperthermia therapy and targeting CD44-overexpressing cancer cells.
Soleymani M; Velashjerdi M; Shaterabadi Z; Barati A
Carbohydr Polym; 2020 Jun; 237():116130. PubMed ID: 32241421
[TBL] [Abstract][Full Text] [Related]
11. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
13. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment.
Zhang X; Zhao M; Cao N; Qin W; Zhao M; Wu J; Lin D
Biomater Sci; 2020 Mar; 8(7):1885-1896. PubMed ID: 32022813
[TBL] [Abstract][Full Text] [Related]
14. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
15. Near infrared fluorescent nanoparticles based on hyaluronic acid: Self-assembly, optical properties, and cell interaction.
Kelkar SS; Hill TK; Marini FC; Mohs AM
Acta Biomater; 2016 May; 36():112-21. PubMed ID: 26995504
[TBL] [Abstract][Full Text] [Related]
16. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
17. CD44-Targeted Photoactivatable Polymeric Nanosystem with On-Demand Drug Release as a "Photoactivatable Bomb" for Combined Photodynamic Therapy-Chemotherapy of Cancer.
Lan JS; Zeng RF; Li Z; Wu Y; Liu L; Chen LX; Liu Y; He YT; Zhang T; Ding Y
ACS Appl Mater Interfaces; 2023 Jul; 15(29):34554-34569. PubMed ID: 37462246
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid/polyethylene glycol nanoparticles for controlled delivery of mitoxantrone.
Sargazi A; Kamali N; Shiri F; Heidari Majd M
Artif Cells Nanomed Biotechnol; 2018 May; 46(3):500-509. PubMed ID: 28503952
[TBL] [Abstract][Full Text] [Related]
19. Boronic acid-tethered amphiphilic hyaluronic acid derivative-based nanoassemblies for tumor targeting and penetration.
Jeong JY; Hong EH; Lee SY; Lee JY; Song JH; Ko SH; Shim JS; Choe S; Kim DD; Ko HJ; Cho HJ
Acta Biomater; 2017 Apr; 53():414-426. PubMed ID: 28216300
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.
Edelman R; Assaraf YG; Levitzky I; Shahar T; Livney YD
Oncotarget; 2017 Apr; 8(15):24337-24353. PubMed ID: 28212584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
